Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2

Journal of Clinical Investigation

Volumn 121, Issue 1, 2011, Pages 120-131

  Ramesh, Sangeetha ^a   Morrell, Craig N ^b   Tarango, Cristina ^a   Thomas, Gail D ^a   Yuhanna, Ivan S ^a   Girardi, Guillermina ^c   Herz, Joachim ^a   Urbanus, Rolf T ^d   De Groot, Philip G ^d   Thorpe, Philip E ^a   Salmon, Jane E ^c   Shaul, Philip W ^a   Mineo, Chieko ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; APOLIPOPROTEIN E2; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN RECEPTOR; NITRIC OXIDE; PHOSPHOLIPID ANTIBODY; PHOSPHOPROTEIN PHOSPHATASE 2A; RECEPTOR ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CAROTID ARTERY; CELL ADHESION; CELL CULTURE; CELL MEMBRANE CONDUCTANCE; CONTROLLED STUDY; DIMERIZATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LEUKOCYTE ENDOTHELIAL CELL ADHESION; MALE; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; CATTLE; CELL ADHESION; DIMERIZATION; ENDOTHELIAL CELLS; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN PHOSPHATASE 2; PROTEIN STRUCTURE, TERTIARY; RNA, SMALL INTERFERING; THROMBOSIS;

EID: 78650961942     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39828     Document Type: Article

References (75)

1. Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
2. Long BR, Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am. 2008;22(1):79-94, vi-vii.
3. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87(11):4120-4124.
4. Galli M, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335(8705):1544-1547.
5. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336(8708):177-178.
6. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102(8):2717-2723.
7. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004;104(12):3598-3602.
8. de Groot PG, et al. Beta2-glycoprotein I and LDL-receptor family members. Thromb Res. 2004;114(5-6):455-459.
9. Pierangeli SS, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008;34(3):236-250.
10. Voetsch B, Jin RC, Loscalzo J. Nitric oxide insufficiency and atherothrombosis. Histochem Cell Biol. 2004;122(4):353-367.
11. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299(3):818-824.
12. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res. 1999;43(3):532-541.
13. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002;64:749-774.
14. Pennings MT, et al. Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost. 2006;4(8):1680-1690.
15. van Lummel M, et al. The binding site in {beta}2-glycoprotein I for ApoER2′ on platelets is located in domain V. J Biol Chem. 2005;280(44):36729-36736.
16. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001;88(2):245-250.
17. Mineo C, et al. FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res. 2005;97(11):1124-1131. (Pubitemid 43755205)
18. Del Papa N, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40(3):551-561.
19. Del Papa N, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995;13(2):179-185.
20. Monestier M, et al. Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. J Immunol. 1996;156(7):2631-2641.
21. Gushiken FC, Arnett FC, Thiagarajan P. Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of beta(2)-glycoprotein I. Am J Hematol. 2000;65(2):160-165.
22. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007;109(4):1490-1494.
23. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105(4):1540-1545.
24. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107(5):1916-1924.
25. de Laat B, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7(11):1767-1773.
26. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95(26):15542-15546.
27. Iverson GM, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002;169(12):7097-7103.
28. Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol. 2006;43(1-2):68-77.
29. Pierangeli SS, Vega-Ostertag M, Liu X, Girardi G. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci. 2005;1051:413-420.
30. Girardi G, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112(11):1644-1654.
31. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222-1226. (Pubitemid 39540439)
32. Holers VM, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195(2):211-220.
33. Arvieux J, Jacob MC, Roussel B, Bensa JC, Colomb MG. Neutrophil activation by anti-beta 2 glycoprotein I monoclonal antibodies via Fc gamma receptor II. J Leukoc Biol. 1995;57(3):387-394.
34. Sammaritano LR, et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum. 1997;40(11):1998-2006.
35. Atsumi T, et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum. 1998;41(5):800-807.
36. Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem. 1991;266(31):21232-21238.
37. Pennings MT, Derksen RH, Urbanus RT, Tekelenburg WL, Hemrika W, de Groot PG. Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemost. 2007;5(7):1538-1544.
38. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost. 2008;6(8):1405-1412.
39. Michell BJ, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem. 2001;276(21):17625-17628.
40. Greif DM, Kou R, Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry. 2002;41(52):15845-15853.
41. Sanz MJ, et al. Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice. Br J Pharmacol. 2001;134(2):305-312.
42. Freedman JE, et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res. 1999;84(12):1416-1421.
43. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100(2):350-356.
44. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation. 1998;98(15):1481-1486.
45. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987;148(3):1482-1489. (Pubitemid 18074679)
46. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992;85(6):2284-2290.
47. Morrell CN, et al. Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A. 2005;102(10):3782-3787.
48. Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res. 2006;118(4):455-461.
49. Mercanoglu F, et al. Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract. 2004;58(11):1003- 1007.
50. de Laat B, et al. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood. 2009;114(17):3656- 3661.
51. Asherson RA, Pierangeli SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66(4):429-432.
52. Cockrell E, Espinola RG, McCrae KR. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus. 2008;17(10):943-951.
53. Raschi E, Borghi MO, Grossi C, Broggini V, Pierangeli S, Meroni PL. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus. 2008;17(10):937-942.
54. Cederholm A, Frostegard J. Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann N Y Acad Sci. 2007;1108:96-103. (Pubitemid 47528722)
55. Sacre SM, Stannard AK, Owen JS. Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett. 2003;540(1-3):181-187.
56. Korschineck I, et al. Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue. J Biol Chem. 2001;276(16):13192-13197.
57. Pennings MT, et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost. 2007;5(2):369-377.
58. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol. 2004;112(2):169-174.
59. Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate vascular endothelial cells. Lupus. 1996;5(5):440-441.
60. Meroni PL, et al. Inflammatory response and the endothelium. Thromb Res. 2004;114(5-6):329-334.
61. Fischetti F, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106(7):2340-2346.
62. Amital H, et al. Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol. 2008;26(1 suppl 48):S27-S32.
63. Kinev AV, Roubey RA. Tissue factor in the antiphospholipid syndrome. Lupus. 2008;17(10):952-958.
64. Zhu W, et al. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res. 2008;102(4):480-487.
65. Babiker A, et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27- hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem. 1997;272(42):26253-26261.
66. Akeson AL, et al. Embryonic vasculogenesis by endothelial precursor cells derived from lung mesenchyme. Dev Dyn. 2000;217(1):11-23.
67. Akeson AL, Brooks SK, Thompson FY, Greenberg JM. In vitro model for developmental progression from vasculogenesis to angiogenesis with a murine endothelial precursor cell line, MFLM-4. Microvasc Res. 2001;61(1):75-86.
68. Green DD, Yang SI, Mumby MC. Molecular cloning and sequence analysis of the catalytic subunit of bovine type 2A protein phosphatase. Proc Natl Acad Sci U S A. 1987;84(14):4880-4884.
69. He J, Luster TA, Thorpe PE. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res. 2007;13(17):5211-5218.
70. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res. 2005;11(4):1551-1562. (Pubitemid 40315240)
71. Trommsdorff M, et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999;97(6):689-701.
72. Yamakuchi M, et al. Exocytosis of endothelial cells is regulated by N-ethylmaleimide-sensitive factor. Methods Mol Biol. 2008;440:203-215.
73. Lefer DJ, et al. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol. 1999;276(6 pt 2):H1943-H1950.
74. Ahluwalia A, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A. 2004;101(5):1386-1391.
75. Morrell CN, et al. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med. 2008;205(3):575-584.